(Reuters) – Johnson & Johnson said on Thursday it had struck a deal with Emergent BioSolutions Inc to use its manufacturing facilities to help in an effort to make more than 1 billion doses of a vaccine it is testing to stop the novel coronavirus.
(Reuters) – Britain’s AstraZeneca is testing a diabetes drug as a potential treatment for COVID-19 patients who also had existing heart and kidney problems, its second trial of an approved therapy to help treat the disease caused by the coronavirus.
French drugmaker Sanofi expects to produce up to 600 million doses of its coronavirus vaccine next year if its clinical trials with GSK go as planned, CEO Paul Hudson said Friday.
The French drug giant Sanofi said Tuesday that it plans to use technology from GlaxoSmithKline to accelerate the development of its experimental vaccine against the novel coronavirus, SARS-CoV-2.
Novartis has entered into a four-year research collaboration with Orionis Biosciences. The agreement tasks Orionis with applying its technologies to “historically elusive targets” in multiple therapeutic areas.
In the hunt for a COVID-19 therapy, some researchers have hit upon a combination of antimalarial hydroxychloroquine and antibiotic azithromycin as a potential answer. So far, clinical results have been mixed at best—but demand for azithromycin has still been sky-high, and drugmakers are feeling the pinch.
(Reuters) – Abbott Laboratories Inc (ABT.N) said on Thursday a recent ramp up in coronavirus tests production would help it ride out a tough current quarter as the outbreak chokes demand for its other diagnostic kits.
(Reuters) – AstraZeneca Plc (AZN.L) said on Tuesday it would start a clinical trial of its cancer drug Calquence to assess its potential to control the exaggerated immune system response associated with COVID-19 infection in severely ill patients.
ZURICH (Reuters) – Novartis subsidiary Sandoz on Wednesday said it would keep prices stable on a basket of medicines which may help to treat coronavirus patients, responding to recent concerns over potential drug shortfalls and price spikes in the wake of the coronavirus break.
